Amgen presenterar nya data på ASH
Amgen presenterar nya data på världens största blodcancerkongress
På lördag den 11 december inleds 63rd Annual Meeting and Exposition of the American Society of Hematology.
– Det är ett bra år för Amgen, säger Sandra Eketorp Sylvan, medicinsk chef för Amgen Sverige. Det gäller dels starka data på Blincyto vid behandling av akut lymfatisk leukemi, inte minst hos barn, dels vår proteasomhämmare Kyprolis som fortsätter att övertyga vid behandling av myelom.
Det återstår att se hur många som kommer att vara på plats och hur många som deltar på distans när American Society of Hematology åter välkomnar hematologer från hela världen till sitt årliga möte, den här gången på Georgia World Congress Center i Atlanta.
Amgen presenterar som vanligt ett stort antal abstracts med nya data för såväl etablerade terapier som för sin innovativa hematologi-pipeline.
– Bland annat ser jag mycket fram emot att ta del av slutanalysen från Master-studien där patienter med nydiagnostiserat myelom behandlats med en kombination av daratumumab, carfilzomib, lenalidomid och dexametason (Dara-KRd) och nått så djupa behandlingssvar att behandlingen kunnat avslutas utan att de progredierat eller återfått MRD, säger Sandra Eketorp Sylvan. Det här väcker hopp om att krävande underhållsbehandling kanske kan komma att ersättas av MRD-övervakning för vissa patienter.
Nedan följer ett urval av de abstracts som Amgen presenterar vid ASH 2021.
Amgen-sponsrade abstracts, myelom och AML
Real World Assessment of Treatment Patterns and Outcomes Among Multiple Myeloma Patients across Different Risk Stratification Criteria in the United States: A Retrospective Cohort Study
Abstract #1640, Poster Presentation, Saturday, Dec. 11 from 5:30 – 7:30 p.m. ET
Outcomes of Triple-Class (proteasome inhibitor, immunomodulator, CD38 monoclonal antibody) Exposed Relapsed or Refractory Multiple Myeloma (RRMM) in United States (US) Real-World Practice
Abstract #3042, Poster Presentation, Sunday, Dec. 12 from 6 – 8 p.m. ET
A Temporal and Multinational Assessment of Acute Myeloid Leukemia (AML) Cancer Incidence, Survival, and Disease Burden
Abstract #4124, Poster Presentation, Monday, Dec. 13 from 6 – 8 p.m. ET
Amgen-sponsrade abstracts, Blincyto
Superior Overall Survival with Blinatumomab Versus Chemotherapy As Pre-Transplant Consolidation Treatment in Children with High-Risk First-Relapse B‑Cell Precursor Acute Lymphoblastic Leukemia (B-ALL): Longer Follow-up (FU) of a Phase 3 Randomized Controlled Trial (RCT)
Abstract #1231, Poster Presentation, Saturday, Dec. 11 from 5:30 – 7:30 p.m. ET
Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Abstract #2303, Poster Presentation, Sunday, Dec. 12 from 6 – 8 p.m. ET
A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin’s Lymphoma (NHL)
Abstract #2436, Poster Presentation, Sunday, Dec. 12 from 6 – 8 p.m. ET
Heterogeneity of Minimal/Measurable Residual Disease (MRD) Practices in Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in the United States
Online Publication
Forskarinitierade abstracts, Blincyto
Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
Abstract #1233, Poster Presentation, Saturday, Dec. 11 from 5:30 – 7:30 p.m. ET
A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children’s Oncology Group Study AALL1331
Abstract #363, Oral Presentation, Sunday, Dec. 12 at 10 a.m. ET
Amgen-sponsrade abstracts, Kyprolis
Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Abstract #1235, Poster Presentation, Saturday, Dec. 11 from 5:30 – 7:30 p.m. ET
Phase 2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Abstract #4403, Online Publication
Forskarinitierade abstracts, Kyprolis
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), AutologousTransplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial
Abstract #481, Oral Presentation, Sunday, Dec. 12 at 12 p.m. ET
Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy
Abstract #483, Oral Presentation, Sunday, Dec. 12 at 12:30 p.m. ET
Nplate-abstracts, kliniska data
Surveillance Program of Romiplostim Use Connected to Pregnancy
Abstract #585, Oral Presentation, Monday, Dec. 13 from 10:30 a.m. – 12 p.m. ET
Romiplostim for the Treatment of Adult Patients with Newly Diagnosed or Persistent Immune Thrombocytopenia: Subgroup Analysis from a Phase 2 Study
Abstract #3157, Poster Presentation, Monday, Dec. 13 from 6 – 8 p.m. ET
Thrombocytopenia Among Patients with Hematologic Malignancies and Solid Tumors: Risk and Prognosis
Abstract #3156, Poster Presentation, Monday, Dec. 13 from 6 – 8 p.m. ET
Investigating the Potential Impact of Dosing Tolerance to Facilitate Use of Nplate Self-Administration in Adult Patients with ITP
Online Publication
Assessing Romiplostim Dose and Platelet Response-Guided Titration to Support Use of Romiplostim in ITP Patients Less Than 12 months From Diagnosis
Online Publication
Forskarinitierade abstracts, Nplate
Immunomodulation with Romiplostim in Young Adult Primary Immune Thrombocytopenia (ITP) As Second-Line Strategy (iROM-study)
Abstract #3149, Poster Presentation, Monday, Dec. 13 from 6 – 8 p.m. ET
